We are live on ! Find out more
ARIA

Ariad Pharmaceuticals Inc
ARIA

Delisted

ARIA was delisted on the 15th of February, 2017.

175 hedge funds and large institutions have $801M invested in Ariad Pharmaceuticals Inc in 2015 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 52 increasing their positions, 62 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more call options, than puts

Call options by funds: $14.3M | Put options by funds: $12.5M

0% more funds holding in top 10

Funds holding in top 10: 55 (0)

8% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 24

1% less funds holding

Funds holding: 177175 (-2)

16% less repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 62

31% less capital invested

Capital invested by funds: $1.16B → $801M (-$358M)

Holders
175
Holders Change
-2
Holders Change %
-1.13%
% of All Funds
4.89%
Holding in Top 10
5
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.14%
New
22
Increased
52
Reduced
62
Closed
24
Calls
$14.3M
Puts
$12.5M
Net Calls
+$1.83M
Net Calls Change
+$2.71M
Name Holding Trade Value Shares
Change
Change in
Stake
Royal Bank of Canada
101
Royal Bank of Canada
Ontario, Canada
$324K +$254K +32,961 +146%
CC
102
CQS Cayman
Cayman Islands
$319K +$421K +54,600 New
ST
103
Spot Trading
Illinois
$308K +$263K +34,194 +185%
AG
104
Aperio Group
California
$303K +$123 +16 +0%
Barclays
105
Barclays
United Kingdom
$301K +$383K +49,699 +472%
HVC
106
Healthcare Value Capital
New Jersey
$292K -$385K -50,000 -50%
Two Sigma Advisers
107
Two Sigma Advisers
New York
$290K -$723K -93,801 -65%
Citadel Advisors
108
Citadel Advisors
Florida
$276K -$924K -119,957 -72%
CIA
109
Capital Impact Advisors
Massachusetts
$263K
LTFS
110
Ladenburg Thalmann Financial Services
Florida
$260K -$18.7K -2,422 -5%
NIT
111
NumerixS Investment Technologies
British Columbia, Canada
$255K +$16.2K +2,100 +5%
AL
112
Airain Ltd
Guernsey
$255K +$336K +43,655 New
CWM
113
Concert Wealth Management
California
$248K -$2.6K -338 -0.8%
NPC
114
National Planning Corporation
California
$225K
Invesco
115
Invesco
Georgia
$216K -$19.7M -2,559,601 -99%
Legal & General Group
116
Legal & General Group
United Kingdom
$210K
BNP Paribas Financial Markets
117
BNP Paribas Financial Markets
France
$201K +$158K +20,503 +147%
PAM
118
Panagora Asset Management
Massachusetts
$201K +$245K +31,778 +1,202%
PNC Financial Services Group
119
PNC Financial Services Group
Pennsylvania
$199K +$2.41K +313 +0.9%
Commonwealth Equity Services
120
Commonwealth Equity Services
Massachusetts
$196K +$24.7K +3,203 +11%
HSBC Holdings
121
HSBC Holdings
United Kingdom
$185K -$30.3K -3,928 -11%
Two Sigma Investments
122
Two Sigma Investments
New York
$178K -$5.19M -673,876 -96%
CNB
123
City National Bank
California
$177K -$2.19M -284,352 -90%
QT
124
Quantbot Technologies
New York
$176K +$182K +23,569 +357%
CAM
125
Congress Asset Management
Massachusetts
$175K

ARIA Hedge Fund Activity: Q3 2015 in Review

175 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q3 2015, worth a combined $801M — down 31% from $1.16B a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of ARIA and 22 opened new positions — a net loss of 2 holders — while 62 trimmed existing stakes and 52 added.

The largest buyer was Putnam Investments, adding an estimated $86.4M. The largest seller was Discovery Capital Management, exiting entirely with an estimated $43.9M sold.

  • 175 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q3 2015, down from 177 in Q2 2015.
  • Funds reported $801M of Ariad Pharmaceuticals Inc stock for Q3 2015, down 31% quarter-over-quarter.
  • 22 funds opened new Ariad Pharmaceuticals Inc positions in Q3 2015 and 24 closed out, a net change of -2 holders.
  • The largest Ariad Pharmaceuticals Inc buyer in Q3 2015 was Putnam Investments, an estimated $86.4M added.
  • The largest Ariad Pharmaceuticals Inc seller in Q3 2015 was Discovery Capital Management, an estimated $43.9M sold.

Based on aggregated 13F filings for Q3 2015.